La chaîne d'options affiche les données clés des options sur actions de CureVac à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour CureVac..

CureVac (NASDAQ:CVAC) Stock, Chaîne d'Options

CureVac

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV

Earnings

Earnings Beats

News

OFIX

Orthofix Medical Q1 Adj. EPS $(0.08) Beats $(0.27) Estimate

Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.38 by 15.79 percent. This is a 21.21 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $5.13 billion which beat the analyst consensus estimate of $4.74 billion by 8.29 percent. This is a 0.02 percent increase over sales of $5.13 billion the same period last year.

Fresenius Medical Care Q1 Adj. EPS $0.44 Beats $0.38 Estimate, Sales $5.13B Beat $4.74B Estimate

BEAT

HeartBeam Announced The Addition Of Two New U.S. Patents, Reinforcing Its Core Intellectual Property Position And Enabling Future Product Extensions

License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies
AUSTIN, Texas, May 6, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4420629-1&amp;h=3461894870&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a>&nbsp;("Genprex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive patent license agreement with UTHealth Houston granting Genprex exclusivity and commercial rights relating to its lead drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid) for the potential treatment of glioblastoma. The subject patent is co-owned by Genprex and UTHealth Houston, and the license provides Genprex with patent exclusivity.
"We are pleased to expand our portfolio of licensed patents and add a technology that uses REQORSA to treat glioblastoma," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. "With this license agreement, Genprex has obtained exclusive commercial rights to REQORSA in glioblastoma while also adding to our patent estate. The role of TUSC2 in lung cancer has been well established, and this latest license enables Genprex to expand the use of REQORSA into a new indication, in which the cancer can be difficult to treat and there are unmet medical needs."
REQORSA may be a potential therapeutic treatment for glioblastoma. Genprex previously <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4420629-1&amp;h=615969523&amp;u=https%3A%2F%2Fwww.genprex.com%2F2024%2F10%2F10%2Fgenprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-the-2024-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-2%2F&amp;a=reported+positive+preclinical+data+on+the+efficacy+of+REQORSA+in+glioblastoma">reported positive preclinical data on the efficacy of REQORSA in glioblastoma</a>&nbsp;in October 2024 at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4420629-1&amp;h=2819980625&amp;u=https%3A%2F%2Fwww.genprex.com%2Fwp-content%2Fuploads%2F2024%2F10%2FENA24-0125-130_Lo.pdf&amp;a=2024+EORTC-NCI-AACR+Symposium+on+Molecular+Targets+and+Cancer+Therapeutics">2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics</a>. Research collaborators from UTHealth Houston previously reported TUSC2 as a novel tumor suppressor for glioblastoma, the most common and deadliest primary brain tumor in adults which is associated with a poor prognosis. In their latest study, UTHealth Houston researchers used patient-derived glioblastoma (GBM) cell lines and patient-derived glioma stem cell (PD-GSC) lines. REQORSA was used to restore TUSC2 expression.

Biotech

General

GNPX

Genprex Enters Exclusive Patent License To Additional Gene Therapy Technology With UTHealth Houston For The Treatment Of Glioblastoma

<ul>
<li>Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026</li>
<li>Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results</li>
</ul>
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the implementation of a strategic restructuring and reprioritization plan aimed at extending the company's cash runway and furthering the development of emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC.

MRSN

Mersana Therapeutics Implements Strategic Restructuring And Reprioritization Plan To Extend Cash Runway, Advance Emi-Le; XMT-1660

Archer-Daniels-Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) affirms FY2025 Adj EPS guidance from $4.00-$4.75 to $4.00-$4.75 vs $4.10 analyst estimate. Archer-Daniels-Midland Reaffirms FY2025 Adj. EPS Outlook of $4.00–$4.75, Expects Results Near Low End Amid Market Challenges

Guidance

Archer-Daniels-Midland Affirms FY2025 Adj EPS Guidance Of $4.00-$4.75 vs $4.10 Est; Expects Results Near Low End Amid Market Challenges

MORN

Morningstar Introduced The Morningstar Medalist Rating For Semiliquid Funds, Expanding Its Established Medalist Rating Framework To The Growing Segment Of Semiliquid Investment Vehicles

TLRY

Tilray Brands Craft Beer Brand Blue Point Brewing Re-Releases Delayed Pilsner Beer

Telesat (CSE2: TSAT) sees FY2025 sales of $405.000 million-$425.000 million vs $416.85 million analyst estimate.

Telesat Sees FY2025 Sales $405.000M-$425.000M vs $416.85M Est

CCCS

CCC Intelligent Solutions Lowers FY2025 Sales Guidance of $1.05B-$1.06B vs $1.06B Est

GENI

Genius Sports  Has Approved A Share Repurchase Program To Repurchase Up To $100M Of Ordinary Shares Of Genius Sports, Given The Strong Business Performance

Telesat (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#TSX">TSAT</a>) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.57) by 89.47 percent. This is unchanged from the same period last year. The company reported quarterly sales of $116.75 million which beat the analyst consensus estimate of $109.24 million by 6.87 percent. This is a 23.28 percent decrease over sales of $152.18 million the same period last year.

Earnings Misses

TSX:TSAT

Telesat Q1 EPS $(1.08) Misses $(0.57) Estimate, Sales $116.75M Beat $109.24M Estimate

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4420174-1&amp;h=1400567367&amp;u=https%3A%2F%2Fwww.iridium.com%2F&amp;a=Iridium+Communications+Inc.">Iridium Communications Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), a leading provider of global voice and data satellite communications, today announced a special U.S. government version of the Iridium&#xAE; 9603 module built for Enhanced Short Burst Data (ESBD). ESBD is a low-latency and secure messaging service designed to provide optimal transmission security (TRANSEC) for the U.S. government and approved allies.
The ESBD version can act as a drop-in replacement for the existing Iridium 9603 Short Burst Data&#xAE; (SBD&#xAE;) module. Alongside Iridium's known reliability and resiliency, Iridium 9603 ESBD can deliver secure one- or two-way messaging with an increased payload capacity for mobile-originated (MO) and mobile-terminated (MT) messages. Example applications range from command and control (C2) and image data transfer to personnel and asset tracking.
"Iridium 9603 ESBD is a testament to Iridium's commitment to investing in secure, low-latency solutions that address threats in the changing global environment," said Scott Scheimreif, executive vice president, government programs, Iridium.&nbsp;"The new module offers end-to-end communication security for critical operations, helping ensure warfighters can exchange vital information with confidence — no matter the environment. This capability not only safeguards mission success but also reflects the Department of Defense's trust in Iridium's proven technology, network reliability, and operational excellence."
The upgraded module represents the latest innovation of Iridium to support the Enhanced Mobile Satellite Services (EMSS) program, a decades-long partnership that delivers truly global standard and secure voice, broadcast, PTT, and other services to an unlimited number of Department of Defense and DoD-approved subscribers anywhere on Earth. Iridium 9603 ESBD is targeted to be made available to EMSS-approved value-added manufacturers in July.
With its unique low-Earth orbit (LEO) satellite network, Iridium provides resilient L-band connectivity and unparalleled global coverage that does not encounter permanent line-of-sight blockages faced by geostationary (GEO) systems. This helps to ensure the delivery of mission-critical communications for the DoD and other federal agencies. Whether in high-risk combat zones or during inclement weather events, the Iridium network provides pole-to-pole satellite communications that keep users connected when it's needed most, making it critically important for the Joint All Domain Command and Control's (JADC2) Primary, Alternate, Contingency, and Emergency (PACE) communications

Contracts

IRDM

Iridium Communications Releases A Special U.S. Government Version Of The Iridium 9603 Module Built For Enhanced Short Burst Data

HF Foods Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFFG#NASDAQ">HFFG</a>), a distributor in the Asian specialty food sector, announced Tuesday that it is broadening its digital presence through the launch of a new online ordering platform tailored for restaurant staff.
Over the next few months, HF Foods plans to introduce its new digital platform to a targeted group of customers.
The system will allow restaurant staff and proprietors to buy the company's premium, authentic specialty products directly, utilizing the same delivery network currently in place for restaurant orders.
"We're expanding our service model in a way that drives growth, strengthens customer loyalty and operates with virtually no incremental delivery cost. This platform launch is a key part of our transformation plan and a meaningful catalyst for our continued operational excellence," said President and CEO Felix Lin.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/restaurants/25/05/45177147/mcdonalds-stumbles-on-weak-traffic-despite-margin-gains-and-analyst-optimism" rel="noreferrer noopener">McDonald's Stumbles On Weak Traffic, Despite Margin Gains And Analyst Optimism</a>
HF Foods' newest offering gives both restaurant owners and their staff the ability to browse and order from the company's wide range of specialty food items through a simplified online platform.
This setup uses the existing delivery network used for Asian restaurants nationwide, allowing the company to grow its reach without requiring additional spending on logistics infrastructure.
By extending its offerings directly to people working in the restaurant sector, HF Foods seeks to strengthen customer connections and build long-term brand trust.
"We believe major industry players have historically underserved the specialty and international foodservice market," added Lin.
"As a result, people may have difficulty accessing the specialty products that they want due to proverbial ‘food deserts' throughout the country. Our e-commerce platform is another way that HF Foods solves this need and continues to be an all-in-one source for quick, easy and economical ordering of specialty and international foods in the United States.
HF Foods is introducing the platform gradually across selected U.S. regions, beginning with its hubs in North Carolina, Florida, and Utah.
Coinciding with the e-commerce rollout, HF Foods unveiled a redesigned logo featuring a green-and-gold color palette and incorporating an infinity symbol, signifying a commitment to innovation and efficient logistics.
The company's new slogan: "Specialty Food is Our Specialty," reflects the company's intention to grow into new segments of the international restaurant market.
Price Action: HFFG shares traded higher by 1.60% at $3.80 in premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45194848/footwear-giant-skechers-to-go-private-in-more-than-9b-deal-with-3g-capital-stock-surges" target="_blank" rel="noreferrer noopener">Footwear Giant Skechers To Go Private At 30% Premium In PE Deal</a></li>
</ul>
Photo via Shutterstock

Market-Moving Exclusives

Exclusives

HFFG

Exclusive: HF Foods Launches E-Commerce Platform For Restaurant Staff Nationwide

CCLD

CareCloud Affirms FY2025 GAAP EPS Guidance of $0.10-$0.13 vs $0.09 Est; Affirms FY2025 Sales Guidance of $111.00M-$114.00M vs $112.11M Est

-- PAS-004 shows up to 91% inhibition of pERK, confirming substantial target engagement --
-- One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable disease with tumor volume reduction of -9.8% --
MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=X4a-KuP24GJRcQd0BJ0hQl1heO9K8kGQRsx2TNpmjXbbwIXjZKiD5EJCpYfRPDqFcymhV2SfdDkqYEpPxdtkcyWE4AvOyY2cNHS2kuMl9mo=">Pasithea Therapeutics Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven cancer indications, today announced positive interim pharmacodynamic (PD) data from its ongoing Phase 1 trial of PAS-004 in advanced cancer patients. The data includes results from cohorts 3 and 4A, evaluating 8mg and 15mg capsules, as well as cohort 4B evaluating 4mg tablets, and demonstrates strong target engagement consistent with PAS-004's favorable pharmacological profile.
Inhibition of ERK phosphorylation (pERK) is widely recognized as a gold-standard PD biomarker for assessing MEK inhibitor activity. To evaluate target engagement, pERK levels were measured in peripheral blood mononuclear cells (PBMCs) collected from patients at baseline and steady-state at day 22.
Preliminary results demonstrate robust pERK inhibition, with reductions in pERK levels of up to 91% even at the 8mg dose level, in line with a previous developed PK/PD model, confirming substantial target engagement in patients receiving PAS-004.

KTTA

Pasithea Announces Interim PD Data From Ongoing Phase 1 Trial Of PAS-004 In Advanced Cancer Patients; PAS-004 Shows Up To 91% Inhibition Of pERK, Confirming Substantial Target Engagement

Rosenblatt analyst Mike Genovese maintains Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Buy and raises the price target from $230 to $250.

Price Target

Analyst Ratings

Rosenblatt Maintains Buy on Fabrinet, Raises Price Target to $250

Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) sees Q2 sales of $155.000 million-$157.000 million vs $155.80 million analyst estimate.

XMTR

Xometry Sees Q2 Sales $155.000M-$157.000M vs $155.80M Est

CCC Intelligent Solutions Sees Q2 Sales $255.500M-$257.500M vs $259.30M Est

Sealed Air (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) affirms FY2025 Adj EPS guidance from $2.90-$3.30 to $2.90-$3.30 vs $3.09 analyst estimate. Affirms FY2025 sales outlook from $5.10 billion-$5.50 billion to $5.10 billion-$5.50 billion vs $5.31 billion estimate.

Sealed Air Affirms FY2025 Adj EPS Guidance of $2.90-$3.30 vs $3.09 Est; Affirms FY2025 Sales Guidance of $5.10B-$5.50B vs $5.31B Est

Events

Press Releases

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

Management

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Comments

CureVac

CureVac (CVAC) Options

CureVac (NASDAQ:CVAC) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL